Publication:
Sodium fusidate-poly(D,L-lactide-co-glycolide) microspheres: Preparation, characterisation and in vivo evaluation of their effectiveness in the treatment of chronic osteomyelitis

dc.contributor.authorDURMUŞOĞLU, LÜTFİYE
dc.contributor.authorsCevher, Erdal; Orhan, Zafer; Sensoy, Demet; Ahiskali, Rengin; Kan, Pei Lee; Sagirli, Olcay; Mulazimoglu, Lutfiye
dc.date.accessioned2022-03-12T17:33:19Z
dc.date.accessioned2026-01-11T08:42:50Z
dc.date.available2022-03-12T17:33:19Z
dc.date.issued2007
dc.description.abstractPurpose: The aim of this study was to prepare poly(D, L- lactide-co-glycolide) (PLGA) microspheres containing sodium fusidate ( SF) using a double emulsion solvent evaporation method with varying polymer: drug ratios (1: 1, 2.5: 1, 5: 1) and to evaluate its efficiency for the local treatment of chronic osteomyelitis. Methods: The particle size and distribution, morphological characteristics, thermal behaviour, drug content, encapsulation efficiency and in vitro release assessments of the formulations had been carried out. Sterilized SF-PLGA microspheres were implanted in the proximal tibia of rats with methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. After 3 weeks of treatment, bone samples were analysed with a microbiological assay. Results: PLGA microspheres between the size ranges of 2.16-4.12 mu m were obtained. Production yield of all formulations was found to be higher than 79% and encapsulation efficiencies of 19.8-34.3% were obtained. DSC thermogram showed that the SF was in an amorphous state in the microspheres and the glass transition temperature ( Tg) of PLGA was not influenced by the preparation procedure. In vitro drug release studies had indicated that these microspheres had significant burst release and their drug release rates were decreased upon increasing the polymer: drug ratio (p < 0.05). Based on the in vivo data, rats implanted with SF-PLGA microspheres and empty microspheres showed 1987 +/- 1196 and 55526 +/- 49086 colony forming unit of MRSA in 1 g bone samples (CFU/g), respectively (p < 0.01).
dc.identifier.doi10.1080/02652040701472584
dc.identifier.eissn1464-5246
dc.identifier.issn0265-2048
dc.identifier.pubmed17654177
dc.identifier.urihttps://hdl.handle.net/11424/228817
dc.identifier.wosWOS:000247967100007
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.relation.ispartofJOURNAL OF MICROENCAPSULATION
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectsodium fusidate
dc.subjectpoly(D,L-lactide-co-glycolide) microspheres
dc.subjectemulsion solvent evaporation method
dc.subjectmethicillin-resistant Staphylococcus aureus
dc.subjectchronic osteomyelitis
dc.subjectRESISTANT STAPHYLOCOCCUS-AUREUS
dc.subjectCIPROFLOXACIN IMPLANTS
dc.subjectBONE IMPLANTATION
dc.subjectFUSIDIC ACID
dc.subjectLACTIC-ACID
dc.subjectVITRO
dc.subjectMICROPARTICLES
dc.subjectFORMULATION
dc.subjectVANCOMYCIN
dc.subjectSIZE
dc.titleSodium fusidate-poly(D,L-lactide-co-glycolide) microspheres: Preparation, characterisation and in vivo evaluation of their effectiveness in the treatment of chronic osteomyelitis
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage595
oaire.citation.issue6
oaire.citation.startPage577
oaire.citation.titleJOURNAL OF MICROENCAPSULATION
oaire.citation.volume24

Files